LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

Search

Cogent Biosciences Inc

Затворен

7.26 0.55

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

6.92

Максимум

7.27

Ключови измерители

By Trading Economics

Приходи

-4.1M

-72M

EPS

-0.525

Служители

205

EBITDA

-1.2M

-74M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+128.22% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

172M

806M

Предишно отваряне

6.71

Предишно затваряне

7.26

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Cogent Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.06.2025 г., 18:52 ч. UTC

Печалби

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

22.06.2025 г., 23:59 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Worries Over Middle East Conflict -- Market Talk

22.06.2025 г., 23:55 ч. UTC

Пазарно говорене

Markets Wait to See if Iran's Response Will be Symbolic or Substantial -- Market Talk

22.06.2025 г., 23:51 ч. UTC

Пазарно говорене

Oil Climbs After U.S. Attack on Iran's Nuclear Sites -- Market Talk

22.06.2025 г., 23:43 ч. UTC

Пазарно говорене

Reasons to Believe Strait of Hormuz Will Remain Open -- Market Talk

22.06.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Fall as Middle East Uncertainty Persists -- Market Talk

22.06.2025 г., 23:11 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.06.2025 г., 23:11 ч. UTC

Пазарно говорене

Early Market Reaction to Iran Attacks Restrained -- Market Talk

22.06.2025 г., 22:59 ч. UTC

Пазарно говорене

Gold, Silver Rise as Investors Seek Haven After Strikes on Iran -- Market Talk

22.06.2025 г., 21:43 ч. UTC

Пазарно говорене

Australian Govt Says Supports US Strikes On Iran -- Market Talk

21.06.2025 г., 08:20 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

21.06.2025 г., 08:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

21.06.2025 г., 08:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

20.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.06.2025 г., 20:13 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20.06.2025 г., 20:11 ч. UTC

Пазарно говорене

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20.06.2025 г., 19:56 ч. UTC

Пазарно говорене

Crude Oil Slips to End Week -- Market Talk

20.06.2025 г., 18:35 ч. UTC

Пазарно говорене

Warehouse Clubs Seen Growing Market Share -- Market Talk

20.06.2025 г., 18:12 ч. UTC

Пазарно говорене

Gold Slides to Close Shortened Week -- Market Talk

20.06.2025 г., 17:56 ч. UTC

Пазарно говорене

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20.06.2025 г., 17:50 ч. UTC

Печалби
Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20.06.2025 г., 17:35 ч. UTC

Придобивния, сливания и поглъщания

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20.06.2025 г., 17:30 ч. UTC

Пазарно говорене
Печалби

Adobe's AI Headwinds Seen Fading -- Market Talk

20.06.2025 г., 17:03 ч. UTC

Печалби

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20.06.2025 г., 16:50 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

20.06.2025 г., 16:50 ч. UTC

Пазарно говорене
Печалби

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20.06.2025 г., 16:44 ч. UTC

Придобивния, сливания и поглъщания

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20.06.2025 г., 16:40 ч. UTC

Пазарно говорене
Печалби

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cogent Biosciences Inc Прогноза

Ценова цел

By TipRanks

128.22% нагоре

12-месечна прогноза

Среден 16.5 USD  128.22%

Висок 25 USD

Нисък 7 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Cogent Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

7

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

4.88 / 5.87Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Strong Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.